MA46965B1 - Modulateurs de gamma ror (rory) - Google Patents
Modulateurs de gamma ror (rory)Info
- Publication number
- MA46965B1 MA46965B1 MA46965A MA46965A MA46965B1 MA 46965 B1 MA46965 B1 MA 46965B1 MA 46965 A MA46965 A MA 46965A MA 46965 A MA46965 A MA 46965A MA 46965 B1 MA46965 B1 MA 46965B1
- Authority
- MA
- Morocco
- Prior art keywords
- rory
- ror
- modulators
- gamma
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
La présente invention concerne des composés selon (formule ia) ou (formule ib) : (formule ia) (formule ib) ou un sel pharmaceutiquement acceptable de ceux-ci. Les composés peuvent être utilisés en tant qu'inhibiteurs du rory et sont utiles pour le traitement de maladies à médiation assurée par rory.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202175 | 2016-12-05 | ||
| PCT/EP2017/081489 WO2018104288A1 (fr) | 2016-12-05 | 2017-12-05 | MODULATEURS DE ROR GAMMA (RORγ) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46965B1 true MA46965B1 (fr) | 2020-12-31 |
Family
ID=57482312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46965A MA46965B1 (fr) | 2016-12-05 | 2017-12-05 | Modulateurs de gamma ror (rory) |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10196350B2 (fr) |
| EP (1) | EP3548016B1 (fr) |
| JP (1) | JP6955563B2 (fr) |
| KR (1) | KR102554776B1 (fr) |
| CN (1) | CN110352054B (fr) |
| AR (1) | AR110481A1 (fr) |
| AU (1) | AU2017373593B2 (fr) |
| CL (1) | CL2019001406A1 (fr) |
| CO (1) | CO2019007186A2 (fr) |
| CR (1) | CR20190321A (fr) |
| DK (1) | DK3548016T3 (fr) |
| DO (1) | DOP2019000119A (fr) |
| EA (1) | EA201991373A1 (fr) |
| EC (1) | ECSP19047767A (fr) |
| ES (1) | ES2830759T3 (fr) |
| HU (1) | HUE052470T2 (fr) |
| IL (1) | IL267045B (fr) |
| LT (1) | LT3548016T (fr) |
| MA (1) | MA46965B1 (fr) |
| MX (1) | MX389171B (fr) |
| MY (1) | MY194174A (fr) |
| NZ (1) | NZ755105A (fr) |
| PE (1) | PE20191545A1 (fr) |
| PH (1) | PH12019501231A1 (fr) |
| PL (1) | PL3548016T3 (fr) |
| PT (1) | PT3548016T (fr) |
| RS (1) | RS60964B1 (fr) |
| TW (1) | TWI705958B (fr) |
| UA (1) | UA123751C2 (fr) |
| UY (1) | UY37507A (fr) |
| WO (1) | WO2018104288A1 (fr) |
| ZA (1) | ZA201902288B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101009A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| UY37507A (es) | 2016-12-05 | 2018-06-29 | Lead Pharma Holding Bv | Moduladores de ror gamma (ror¿) |
| WO2023232870A1 (fr) | 2022-05-31 | 2023-12-07 | Immunic Ag | Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008505080A (ja) | 2004-07-01 | 2008-02-21 | ニューヨーク ユニバーシティー | ＲＯＲγｔ機能の調節のための組成物および方法 |
| WO2011115892A1 (fr) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque |
| WO2013029338A1 (fr) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Nouveaux composés |
| AU2013259624B2 (en) | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| WO2013171729A2 (fr) * | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt |
| US9359315B2 (en) | 2013-09-10 | 2016-06-07 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
| HUE043258T2 (hu) | 2013-12-05 | 2019-08-28 | Lead Pharma Holding Bv | ROR gamma (RORy) modulátorok |
| TW201605797A (zh) | 2013-12-10 | 2016-02-16 | 葛蘭馬克製藥公司 | 作為ror伽馬調節物的雙環雜芳基化合物 |
| WO2015090507A1 (fr) | 2013-12-19 | 2015-06-25 | Merck Patent Gmbh | Tétrahydrotétrazolo[1,5-a]pyrazines utilisées comme inhibiteurs du ror-gamma |
| WO2015101928A1 (fr) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Dérivés de thiophène et de thiazole fusionnés utilisés en tant que modulateurs gamma ror |
| UA121309C2 (uk) | 2014-02-03 | 2020-05-12 | Вітае Фармасьютікалс, Ллс | Дигідропіролопіридинові інгібітори ror-гамма |
| WO2015145371A1 (fr) * | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Modulateurs de ror-gamma et leurs utilisations |
| AU2015247983B2 (en) | 2014-04-14 | 2019-05-16 | Boehringer Ingelheim International Gmbh | Compounds as modulators of ROR gamma |
| MX385357B (es) | 2015-05-15 | 2025-03-18 | Aurigene Discovery Tech Ltd | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma |
| EP3101008A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| EP3101006A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| EP3101005A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| EP3101009A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| EP3101007A1 (fr) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Modulateurs de gamma ror (rory) |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| JPWO2017213137A1 (ja) | 2016-06-09 | 2019-04-04 | アグロカネショウ株式会社 | 新規化合物およびこれを有効成分とする農園芸用薬剤 |
| UY37507A (es) | 2016-12-05 | 2018-06-29 | Lead Pharma Holding Bv | Moduladores de ror gamma (ror¿) |
| JP2019026575A (ja) | 2017-07-27 | 2019-02-21 | アグロカネショウ株式会社 | 新規化合物およびこれを有効成分とする農園芸用殺菌剤 |
-
2017
- 2017-12-01 UY UY0001037507A patent/UY37507A/es not_active Application Discontinuation
- 2017-12-01 US US15/829,226 patent/US10196350B2/en active Active
- 2017-12-01 AR ARP170103382A patent/AR110481A1/es unknown
- 2017-12-01 TW TW106142092A patent/TWI705958B/zh active
- 2017-12-05 CN CN201780074934.1A patent/CN110352054B/zh active Active
- 2017-12-05 HU HUE17826439A patent/HUE052470T2/hu unknown
- 2017-12-05 CR CR20190321A patent/CR20190321A/es unknown
- 2017-12-05 PE PE2019001188A patent/PE20191545A1/es unknown
- 2017-12-05 MX MX2019006517A patent/MX389171B/es unknown
- 2017-12-05 DK DK17826439.6T patent/DK3548016T3/da active
- 2017-12-05 UA UAA201907439A patent/UA123751C2/uk unknown
- 2017-12-05 KR KR1020197019416A patent/KR102554776B1/ko active Active
- 2017-12-05 MA MA46965A patent/MA46965B1/fr unknown
- 2017-12-05 RS RS20201281A patent/RS60964B1/sr unknown
- 2017-12-05 EA EA201991373A patent/EA201991373A1/ru unknown
- 2017-12-05 ES ES17826439T patent/ES2830759T3/es active Active
- 2017-12-05 PT PT178264396T patent/PT3548016T/pt unknown
- 2017-12-05 LT LTEP17826439.6T patent/LT3548016T/lt unknown
- 2017-12-05 MY MYPI2019001957A patent/MY194174A/en unknown
- 2017-12-05 JP JP2019529991A patent/JP6955563B2/ja active Active
- 2017-12-05 AU AU2017373593A patent/AU2017373593B2/en active Active
- 2017-12-05 NZ NZ755105A patent/NZ755105A/en unknown
- 2017-12-05 EP EP17826439.6A patent/EP3548016B1/fr active Active
- 2017-12-05 WO PCT/EP2017/081489 patent/WO2018104288A1/fr not_active Ceased
- 2017-12-05 PL PL17826439T patent/PL3548016T3/pl unknown
-
2018
- 2018-12-19 US US16/225,894 patent/US20190119204A1/en not_active Abandoned
-
2019
- 2019-04-11 ZA ZA2019/02288A patent/ZA201902288B/en unknown
- 2019-05-15 DO DO2019000119A patent/DOP2019000119A/es unknown
- 2019-05-23 CL CL2019001406A patent/CL2019001406A1/es unknown
- 2019-06-02 IL IL267045A patent/IL267045B/en unknown
- 2019-06-03 PH PH12019501231A patent/PH12019501231A1/en unknown
- 2019-07-03 CO CONC2019/0007186A patent/CO2019007186A2/es unknown
- 2019-07-04 EC ECSENADI201947767A patent/ECSP19047767A/es unknown
- 2019-12-11 US US16/710,782 patent/US11299456B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA40769B1 (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA49055B1 (fr) | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf | |
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA46965B1 (fr) | Modulateurs de gamma ror (rory) | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA57379B1 (fr) | Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| MA46462B1 (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret |